Document:

Document

Exhibit 10.2

 AMENDMENT NO. 1 TO TRANSITION AND SEPARATION AGREEMENT
This Amendment No. 1 to Transition and Separation Agreement (the “Amendment”) amends the Transition and Separation Agreement between Dicerna Pharmaceuticals, Inc (the “Company”) and Ralf Rosskamp (“you”) with a letter date of April 16, 2020 and an “Effective 
Date” of April 28, 2020 (the “Agreement”).  This Amendment shall be effective on June 30, 2021. 
WHEREAS, pursuant to the Agreement, you retired from employment and from your position as Chief Medical Officer for the Company effective on September 30, 2020; 
WHEREAS, the Agreement includes a provision for you to perform Consulting Services for a period originally scheduled to end on June 30, 2021, which period is subject to extension pursuant to Section 3(e) of the Agreement; 
WHEREAS, the parties acknowledge that the Consulting Period has not been extended beyond June 30, 2021 pursuant to Section 3(e) of the Agreement or otherwise; 
WHEREAS, the parties do not anticipate that Consulting Services will be requested before June 30, 2021 to an extent that would result in an extension of the Consulting Period pursuant to Section 3(e) of the Agreement; 
WHEREAS, the Company anticipates seeking to have you perform Consulting Services after June 30, 2021; and 
WHEREAS, to induce you to perform Consulting Services as requested beyond June 30, 2021, the Company is prepared to supplement its compensation for Consulting Services for such additional period;  
NOW, THEREFORE, in consideration of the mutual covenants in this Amendment, the Company and you agree as follows: 
1.Terms with initial capitalization that are not otherwise defined in this Amendment shall have the meanings set forth in the Agreement. 
2.In the first sentence of Section 3 of the Agreement, “June 30, 2021” is stricken and replaced by “December 31, 2021.”   
3.Section 3(e) of the Agreement (entitled “Increased Services; Extension”) is stricken and is replaced by the following: 
(e)     Consulting Fee.  For Consulting Services that you perform during the period from July 1, 2021 to December 31, 2021 (the “Extension Period”), in addition to other compensation for your performance of requested Consulting Services as set forth above, the Company shall compensate you at the rate of $400 per hour for your performance of requested Consulting Services (the 

Exhibit 10.2

“Consulting Fee”).  No later than thirty (30) days after the end of each calendar month of the Extension Period during which you perform requested Consulting Services, you shall submit an invoice to the Company specifying the date(s) of performance of requested Consulting Services during such month, the number of hours (to the nearest one-tenth of an hour) of requested Consulting Services performed on each such date and the total number of hours of requested Consulting Services that you performed in such month.  The Company shall issue payment to you for properly invoiced Consulting Fees within thirty (30) days of receipt of your invoice.  For the avoidance of doubt, the Consulting Fees shall be treated as Form 1099 income for federal income tax purposes. 
The remainder of the Agreement is not affected by this Amendment.  Without limiting the foregoing, nothing in this Amendment is intended to affect the continuation of your service relationship with the Company during the Consulting Period, including for purposes of the Equity Documents, pursuant to Section 3(c) of the Agreement. 
The parties agree to the foregoing effective as of June 30, 2021. 
DICERNA PHARMACEUTICALS, INC. 
 

By: /s/ Douglas M. Fambrough                 04/15/2021                   
       Name: Douglas M. Fambrough III    Date
      Title: President & CEO

/s/ Ralf Rosskamp              04/15/2021                   
Ralf Rosskamp    DateDocument

Exhibit 10.3

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

This Amendment No. 1 to Employment Agreement (the “Amendment”) is entered into on April 14, 2021 and amends the Employment Agreement between Dicerna Pharmaceuticals, Inc (the “Company”) and John B. Green (the “Executive”) dated as of February 21, 2020 (the “Agreement”).
WHEREAS, the original Agreement contained a clerical error in describing the amount of the Executive’s salary, which the Company and the Executive desire to correct, effective retroactively to the original date of the Agreement.
NOW, THEREFORE, in consideration of the mutual covenants in this Amendment, the Company and you agree as follows:
1.Terms with initial capitalization that are not otherwise defined in this Amendment shall have the meanings set forth in the Agreement.
2.Section 3(a) of the Agreement is stricken and is replaced by the following:
(e)    Base Salary. Commencing from January 1, 2020, the Company shall pay the Executive base salary at a rate of $17,325 paid twice monthly (which annualizes to $415,800), less withholdings and deductions required and/or permitted by law. The Executive’s base salary shall be paid in conformity with the Company’s payroll practices generally applicable to the Company’s senior executives.
The remainder of the Agreement is not affected by this Amendment.
DICERNA PHARMACEUTICALS, INC.

By:    /s/ Douglas M. Fambrough                 04/14/2021                   
    Name:    Douglas M. Fambrough III    Date
    Title: President & CEO

/s/ John B. Green                04/14/2021                   
John B. Green    DateDocument

Exhibit 10.4

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

This Amendment No. 1 to Employment Agreement (the “Amendment”) is entered into on April 14, 2021 and amends the Employment Agreement between Dicerna Pharmaceuticals, Inc (the “Company”) and Bob D. Brown (the “Executive”) dated as of February 21, 2020 (the “Agreement”).
WHEREAS, the original Agreement contained a clerical error in describing the amount of the Executive’s salary, which the Company and the Executive desire to correct, effective retroactively to the original date of the Agreement.
NOW, THEREFORE, in consideration of the mutual covenants in this Amendment, the Company and you agree as follows:
1.Terms with initial capitalization that are not otherwise defined in this Amendment shall have the meanings set forth in the Agreement.
2.Section 3(a) of the Agreement is stricken and is replaced by the following:
(e)    Base Salary. Commencing from January 1, 2020, the Company shall pay the Executive base salary at a rate of $19,437.50 paid twice monthly (which annualizes to $466,500), less withholdings and deductions required and/or permitted by law. The Executive’s base salary shall be paid in conformity with the Company’s payroll practices generally applicable to the Company’s senior executives.
The remainder of the Agreement is not affected by this Amendment.
DICERNA PHARMACEUTICALS, INC.

By:    /s/ Douglas M. Fambrough                 04/14/2021                   
    Name:    Douglas M. Fambrough III    Date
    Title: President & CEO

/s/ Bob D. Brown                04/15/2021                   
Bob D. Brown    DateDocument

Exhibit 10.5

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

This Amendment No. 1 to Employment Agreement (the “Amendment”) is entered into on April 14, 2021 and amends the Employment Agreement between Dicerna Pharmaceuticals, Inc (the “Company”) and James B. Weissman (the “Executive”) dated as of February 21, 2020 (the “Agreement”).
WHEREAS, the original Agreement contained a clerical error in describing the amount of the Executive’s salary, which the Company and the Executive desire to correct, effective retroactively to the original date of the Agreement.
NOW, THEREFORE, in consideration of the mutual covenants in this Amendment, the Company and you agree as follows:
1.Terms with initial capitalization that are not otherwise defined in this Amendment shall have the meanings set forth in the Agreement.
2.Section 3(a) of the Agreement is stricken and is replaced by the following:
(e)    Base Salary. Commencing from January 1, 2020, the Company shall pay the Executive base salary at a rate of $18,083.33 paid twice monthly (which annualizes to $434,000), less withholdings and deductions required and/or permitted by law. The Executive’s base salary shall be paid in conformity with the Company’s payroll practices generally applicable to the Company’s senior executives.
The remainder of the Agreement is not affected by this Amendment.
DICERNA PHARMACEUTICALS, INC.

By:    /s/ Douglas M. Fambrough                 04/14/2021                   
    Name:    Douglas M. Fambrough III    Date
    Title: President & CEO

/s/ James B. Weissman                04/14/2021                   
James B. Weissman    DateDocument

Exhibit 10.6

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

This Amendment No. 1 to Employment Agreement (the “Amendment”) is entered into on April 14, 2021 and amends the Employment Agreement between Dicerna Pharmaceuticals, Inc (the “Company”) and Ralf Rosskamp (the “Executive”) dated as of February 21, 2020 (the “Agreement”).
WHEREAS, the original Agreement contained a clerical error in describing the amount of the Executive’s salary, which the Company and the Executive desire to correct, effective retroactively to the original date of the Agreement.
NOW, THEREFORE, in consideration of the mutual covenants in this Amendment, the Company and you agree as follows:
1.Terms with initial capitalization that are not otherwise defined in this Amendment shall have the meanings set forth in the Agreement.
2.Section 3(a) of the Agreement is stricken and is replaced by the following:
(e)    Base Salary. Commencing from January 1, 2020, the Company shall pay the Executive base salary at a rate of $19,791.67 paid twice monthly (which annualizes to $475,000), less withholdings and deductions required and/or permitted by law. The Executive’s base salary shall be paid in conformity with the Company’s payroll practices generally applicable to the Company’s senior executives.
The remainder of the Agreement is not affected by this Amendment.
DICERNA PHARMACEUTICALS, INC.

By:    /s/ Douglas M. Fambrough                 04/14/2021                   
    Name:    Douglas M. Fambrough III    Date
    Title: President & CEO

/s/ Ralf Rosskamp              04/14/2021                   
Ralf Rosskamp    Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00327-of-00352.parquet"}]]